View Older Stories View More Recent Stories

Mar 10, 2020 05:30AM Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
Feb 20, 2020 04:31PM Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
Feb 20, 2020 04:31PM Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
Feb 3, 2020 04:30PM Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Feb 3, 2020 04:30PM Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Feb 3, 2020 04:30PM Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Jan 31, 2020 09:32AM Emergent BioSolutions (EBS) Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by EMA
Jan 31, 2020 09:26AM Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
Jan 31, 2020 09:26AM Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
Jan 31, 2020 09:26AM Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
Jan 13, 2020 06:42AM Emergent BioSolutions (EBS) Announces EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Jan 13, 2020 06:40AM Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Jan 13, 2020 06:40AM Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Jan 13, 2020 06:35AM Emergent BioSolutions (EBS) Reports Prelim. FY19 Revenue Results In-Line with Consensus; Provides FY20 Revenue Outlook
Jan 13, 2020 06:30AM Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Jan 13, 2020 06:30AM Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Jan 6, 2020 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Jan 6, 2020 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Dec 20, 2019 01:00PM Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
Dec 20, 2019 01:00PM Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
Nov 22, 2019 08:19AM Emergent BioSolutions (EBS) Presents Positive Immunogenicity Results From Phase 2 Study of Chikungunya VLP Vaccine Candidate
Nov 22, 2019 08:19AM Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
Nov 22, 2019 08:19AM Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
Nov 21, 2019 04:05PM Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
Nov 21, 2019 04:05PM Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
Nov 18, 2019 06:30AM Emergent BioSolutions to Host 2019 Analyst and Investor Day
Nov 18, 2019 06:30AM Emergent BioSolutions to Host 2019 Analyst and Investor Day
Nov 6, 2019 04:05PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Nov 6, 2019 04:05PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Oct 21, 2019 06:30AM Emergent BioSolutions to Host 2019 Analyst & Investor Day
Oct 21, 2019 06:30AM Emergent BioSolutions to Host 2019 Analyst & Investor Day
Oct 10, 2019 06:39AM Emergent BioSolutions (EBS) Granted EMA Prime Designation for Chikungunya Virus VLP Vaccine Candidate
Oct 10, 2019 06:38AM Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
Oct 10, 2019 06:38AM Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
Oct 9, 2019 06:30AM Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
Oct 9, 2019 06:30AM Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
Sep 27, 2019 06:35AM Emergent BioSolutions (EBS) Receives NIH Research Grant to Further Develop AP007
Sep 27, 2019 06:35AM Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
Sep 27, 2019 06:35AM Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
Sep 26, 2019 09:27AM Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
Sep 26, 2019 09:27AM Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
Sep 25, 2019 04:18PM Emergent BioSolutions (EBS) Secures $20M Award from U.S. DoD to Develop Diazepam Auto-Injector for Treatment of Nerve Agent-Induced Seizures
Sep 25, 2019 04:15PM Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
Sep 25, 2019 04:15PM Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
Sep 3, 2019 06:32AM Emergent BioSolutions (EBS) Awarded 10-Year HHS Contract to Deliver ACAM2000 Into Strategic National Stockpile
Sep 3, 2019 06:30AM Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
Sep 3, 2019 06:30AM Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
Aug 14, 2019 04:15PM Emergent BioSolutions to Participate in Series of Investor Conferences
Aug 14, 2019 04:15PM Emergent BioSolutions to Participate in Series of Investor Conferences
Aug 1, 2019 04:05PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
View More Recent Stories View Older Stories